BCR and acute lymphoblastic leukemia: Clinical data showed that patients with ZNF384 rearrangements have significantly higher CD123 expression than those with non-ZNF384 rearrangements (BCR-ABL, KMT2A rearrangement, and other B-ALL) [27].